Cooperation on Development Efforts Clause Samples
The Cooperation on Development Efforts clause requires parties to actively collaborate and share resources or information during the development phase of a project or product. In practice, this may involve regular meetings, joint planning sessions, or the exchange of technical data to ensure both parties are aligned and contributing effectively. The core function of this clause is to facilitate smooth progress and maximize the chances of successful development by fostering open communication and mutual support.
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of Licensed Products, Genentech shall keep XOMA informed of all substantive development activities in the Genentech Territory. Genentech shall consider in good faith any comments made by XOMA. Both Parties agree that they will do nothing during Licensed Product development activities to intentionally imperil Regulatory Approvals in any country in any territory which has the potential to be a major economic market.
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of Licensed Product, each Party shall keep the other Party fully informed of all substantive development activities in the Licensed Territory and the United States, as the case may be. The Parties agree that they will do nothing during Licensed Product development activities to imperil early Regulatory Approvals in any country in ---------- *_____* Indicates that material has been omitted and confidential treatment has been requested therefor. All such omitted material has been filed separately with Secretary of the Commission in the Company's Application Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of C2B8, Genentech shall keep IDEC informed of all substantive development activities in the Licensed Territory, and agrees to use its good faith efforts to have an IDEC representative attend meetings of any development committee or similar body governing development activities of Licensed Products in the Licensed Territory. Genentech shall consider in good faith any comments made by such IDEC representative. The
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of C2B8, Genentech shall keep IDEC informed of all substantive development activities in the Licensed Territory, and agrees to use its good faith efforts to have an IDEC representative attend meetings of any development committee or similar body governing development activities of Licensed Products in the Licensed Territory. Genentech shall consider in good faith any comments made by such IDEC representative. The Parties agree that they will do nothing during C2B8 development activities to imperil early Regulatory Approvals in any country in any territory. Genentech further agrees that its European development plan for Licensed Products will not specify clinical trials on a time line that would delay or slow Regulatory Approval in the United States. [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of C2B8, Genentech shall keep IDEC informed of all substantive development activities in the Licensed Territory, and agrees to use its good faith efforts to have an IDEC representative attend meetings of any development committee or similar body governing development activities of Licensed Products in the Licensed Territory. Genentech shall consider in good faith any comments made by such IDEC representative. The Parties agree that they will do nothing during C2B8 development activities to imperil early Regulatory Approvals in any country in any territory. Genentech further agrees that its European development plan for Licensed Products will not specify clinical trials on a time line that would delay or slow Regulatory Approval in the United States.
Cooperation on Development Efforts. To facilitate cooperation between the Parties on the worldwide development and marketing of C2B8, Genentech shall keep IDEC informed of all substantive development activities in the Licensed Territory, and agrees to use its good faith efforts to have an IDEC representative attend meetings of any development committee or similar body governing development activities of Licensed Products in the Licensed Territory. Genentech shall consider in good faith any comments made by such IDEC representative. The Parties agree that they will do nothing during C2B8 development activities to imperil early Regulatory Approvals in any country in any territory. Genentech further agrees that its European development plan for Licensed Products will not specify clinical trials on a time line that would delay or slow Regulatory Approval in the United States. ARTICLE 7 MILESTONES, PROFIT SHARING, ROYALTIES AND OTHER PAYMENTS 7.1(a) Payments by Genentech upon Execution of Original Agreement. Genentech made the following payments to IDEC at the times set forth herein or in the operative agreement:
(i) [CONFIDENTIAL TREATMENT REQUESTED], within 10 days of the Original Effective Date;
(ii) [CONFIDENTIAL TREATMENT REQUESTED]; and
(iii) $5,000,000 to purchase shares of IDEC Preferred Stock as set forth in the Stock Purchase Agreement.